Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN)

9 Jan 2020 10:04

Edison Investment Research Limited Edison Investment Research Limited: Edison issues initiation on Silence Therapeutics (SLN) 09-Jan-2020 / 10:03 GMT/BST


 

London, UK, 9 January 2020

Edison issues initiation on Silence Therapeutics (SLN)

We are initiating coverage of Silence Therapeutics (SLN), a developer of siRNA drugs for diseases that can be genetically targeted. Silence has a proprietary platform for developing siRNA therapeutics, the strength of which was highlighted by preclinical development deals with Mallinckrodt and Takeda (details below). The company will also be re-entering the clinic in Q120 with SLN124, its own drug for iron overload. We are initiating with a valuation of £345m or 440p per share.

 

Our initial valuation of £345m or 440p per share is based on a risk-adjusted NPV analysis of the firm's assets and revenue streams and is driven primarily by our valuation of SLN124 (£141m). We forecast that it will require £105m in additional capital to reach profitability in 2026, offset by potential business development deals.

Click here to view the full report.

 

Subscribe to Edison's content to receive reports by email.

All reports published by Edison are free-to-access and available on the website.

 

About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

For more information please contact Edison:

Nathaniel Calloway, +1 646 653 7036

healthcare@edisongroup.com

 

Learn more at www.edisongroup.com and connect with Edison on:

LinkedIn https://www.linkedin.com/company/edison-group-

Twitter  www.twitter.com/Edison_Inv_Res

YouTube www.youtube.com/edisonitv


Dissemination of a CORPORATE NEWS, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

949913 09-Jan-2020 

corporate announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
22nd Oct 200712:49 pmPRNHolding(s) in Company
9th Oct 200710:58 amPRNIssue of Equity
2nd Oct 20071:30 pmPRNDirector/PDMR Shareholding
28th Sep 20077:00 amPRNHalf-yearly Report
26th Sep 200711:28 amPRNHolding(s) in Company
10th Sep 20077:00 amPRNResearch Update
6th Sep 20077:05 amPRNNotice of Results
4th Sep 20077:30 amPRNHolding(s) in Company
24th Aug 20074:10 pmPRNHolding(s) in Company
23rd Aug 200712:45 pmPRNHolding(s) in Company
20th Aug 20071:08 pmPRNHolding(s) in Company
16th Aug 200710:12 amPRNHolding(s) in Company
15th Aug 20073:25 pmPRNAIM Rule 26
15th Aug 20072:52 pmPRNHolding(s) in Company
9th Aug 20072:18 pmPRNHolding(s) in Company
9th Aug 20077:01 amRNSHolding(s) in Company
2nd Aug 20073:53 pmPRNHolding(s) in Company
2nd Aug 200710:55 amPRNResult of AGM
31st Jul 200710:27 amPRNTotal Voting Rights
31st Jul 20077:00 amPRNRe Agreement
27th Jul 20077:00 amPRNDirectorate Change
27th Jul 20077:00 amPRNDirectorate Change
20th Jul 200711:35 amPRNHolding(s) in Company
13th Jul 20074:09 pmPRNHolding(s) in Company
11th Jul 20073:37 pmPRNHolding(s) in Company
10th Jul 200712:56 pmPRNHolding(s) in Company
9th Jul 20072:27 pmPRNNotice of AGM
9th Jul 200711:01 amPRNHolding(s) in Company
6th Jul 20074:51 pmPRNIssue of Equity
6th Jul 20071:00 pmPRNRe Agreement
2nd Jul 20074:06 pmPRNIssue of Equity
29th Jun 20077:00 amPRNAnnual Report and Accounts
26th Jun 200711:33 amPRNTotal Voting Rights
21st Jun 20073:28 pmPRNHolding(s) in Company
20th Jun 20071:55 pmPRNCorrection : Holding(s) in Company
15th Jun 20077:00 amRNSConference Attendance
14th Jun 20077:00 amPRNIssue of Equity
13th Jun 20073:20 pmPRNHolding(s) in Company
6th Jun 200711:15 amPRNHolding(s) in Company
30th May 20077:05 amPRNHolding(s) in Company
29th May 20074:20 pmPRNHolding(s) in Company
29th May 200710:44 amPRNHolding(s) in Company
21st May 20073:37 pmPRNIssue of Equity
11th May 20074:26 pmPRNHolding(s) in Company
9th May 200711:45 amPRNIssue of Equity
4th May 20077:01 amRNSSR Pharma Name Change
30th Apr 20071:50 pmPRNTotal Voting Rights
26th Apr 200710:30 amPRNEGM Statement & Research Update
23rd Apr 20077:05 amPRNIssue of Equity
3rd Apr 20079:45 amPRNDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.